Incretin manipulation in diabetes management
Incretin manipulation in diabetes management作者机构：Department of Endocrinology and Diabetes New Cross Hospital the Royal Wolverhampton Hospital NHS Trust Department of Medicine Kottayam Medical College Department of Endocrinology Lincoln County Hospital
出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)
年 卷 期：2015年第6卷第6期
页 面：774-781页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Incretin hormones Incretin-based therapies Glucagon-like peptide-1 analogues Dipeptidyl peptidase-4inhibitors Pancreatitis
摘 要：Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus(T2DM) in the 21 st century. Glucagon-like peptide-1(GLP-1) suppresses appetite and gastric motility, and has trophic effects on pancreas, cardio-protective and renal effects. GLP-1 analogues and dipeptidyl peptidase-4 inhibitors form the incretin-based therapies. Significant reduction of hemoglobin A1 c when used as monotherapy and in combination regimens, favorable effects on body weight, and low risk of hypoglycemia are their unique therapeutic benefits. Their safety and tolerability are comparable to other anti-diabetic medications. Concern about elevated risk of pancreatitis has been discarded by two recent meta-analyses. This article discusses the therapeutic manipulation of incretin system for the management of T2 DM.
维普期刊数据库